Oramed officer Joshua Hexter proposes $140K share sale
The notice also lists 137,000 shares sold on July 1, 2026, for $611,433.85 during the prior three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oramed Pharmaceuticals Inc. officer Joshua Hexter reported a proposed sale of 30,000 common shares, with an aggregate market value of $140,100.00 and a sale date of October 1, 2026. The sale is pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. A separate securities table lists 108,000 and 27,000 common shares issued upon vesting of RSUs on May 1, 2023.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
RSUs financial
Rule 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.